University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
Stanford Antimicrobial Safety and Sustainability Program, Stanford, CA, USA.
BMC Infect Dis. 2022 Nov 16;22(1):855. doi: 10.1186/s12879-022-07864-8.
Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia.
This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia.
During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups.
Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment.
先前的研究已经表明,万古霉素耐药肠球菌(VRE)菌血症持续 4 天或以上是死亡的独立预测因素。尽管如此,目前尚无发表的数据来确定那些发生持续性 VRE 菌血症风险最高的患者。
这是一项单中心、回顾性、病例对照研究,纳入了患有 VRE 血流感染(BSI)的成年患者。病例组为持续性菌血症(尽管进行了 VRE 靶向治疗,但持续时间≥4 天)患者,对照组为非持续性菌血症患者。采用逻辑回归评估与持续性 VRE BSI 相关的危险因素。次要结局包括院内死亡率、复发性菌血症和突破性菌血症。
在研究期间,24/108(22%)患者的血培养持续阳性。持续性菌血症的危险因素包括严重中性粒细胞减少症(OR 2.13)、4 个阳性血培养瓶(OR 11.29)和缺乏源头控制(OR 11.88)。在未调整分析中,两组之间的院内死亡率(58%与 40%;p=0.121)、复发性菌血症(17%与 6%;p=0.090)或突破性菌血症(13%与 7%;p=0.402)无统计学显著差异。
尽管进行了靶向抗生素治疗,但严重中性粒细胞减少症、4 个阳性血培养瓶和缺乏源头控制的患者更有可能发生持续性 VRE 菌血症。